-
SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS INC. et al DC CAFC
- 1:13-cv-04740
- D.N.J.
- Judge: Renee Marie Bumb +1
- Filed: 08/07/2013
- Closed: 02/18/2016
- Latest Docket Entry: 05/05/2017
- PACER
- Docket updated daily
1
Plaintiff
5
Defendants
1
Accused
Product
2
Patents-in-Suit
926
Days in
Litigation
-
SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS INC. et al DC CAFC
- 1:13-cv-04740
- D.N.J.
- Judge: Renee Marie Bumb +1
- Filed: 08/07/2013
- Closed: 02/18/2016
- Latest Docket Entry: 05/05/2017
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
6 |
The method of claim 1, wherein the amount of oxcarbazepine is effective to produce a steady state blood level of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 10 μg/ml.
|
Valid
Entry 115 |
7 |
The method of claim 1, wherein the formulation is effective in minimizing fluctuations between C<sub>min </sub>and C<sub>max </sub>of monohydroxy derivative of oxcarbazepine.
|
Valid
Entry 115 |
8 |
The method of claim 7, which provides C<sub>max </sub>levels of monohydroxy derivative of oxcarbazepine in the range of about 6 μg/ml to about 10 μg/ml and C<sub>min </sub>levels of monohydroxy derivative of oxcarbazepine in the range of about 2
view more
|
Valid
Entry 115 |
11 |
The method of claim 10, wherein the formulation is in the form of tablets.
|
Valid
Entry 115 |
18 |
The method of claim 1, wherein the polymer having pH-dependent solubility dissolves at pH values of more than 5.
|
Valid
Entry 115 |
19 |
The method of claim 1, wherein the polymer having pH-dependent solubility dissolves at pH values of more than 6.
|
Valid
Entry 115 |
21 |
The method of claim 1, wherein the formulation is administered once a day.
|
Valid
Entry 115 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising a homogeneous matrix comprising: (a) oxcarbazepine; (b) a matrix-forming polymer selected from the group consisting of cellulosic polymers, alginates, gums,
view more
|
Valid
Entry 115 |
6 |
The pharmaceutical formulation of claim 1, wherein the amount of oxcarbazepine is effective to produce a steady state blood level of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 10 μg/ml.
|
Valid
Entry 115 |
7 |
The pharmaceutical formulation of claim 1 wherein the formulation is effective in minimizing fluctuations between C<sub>min </sub>and C<sub>max </sub>of monohydroxy derivative of oxcarbazepine.
|
Valid
Entry 115 |
8 |
The pharmaceutical formulation of claim 7, which provides C<sub>max </sub>levels of monohydroxy derivative of oxcarbazepine in the range of about 6 μg/ml to about 10 μg/ml and C<sub>min </sub>levels of monohydroxy derivative of oxcarbazepine in the
view more
|
Valid
Entry 115 |
11 |
The formulation of claim 10 in the form of tablets.
|
Valid
Entry 115 |
18 |
The pharmaceutical formulation of claim 1, wherein the polymer having pH-dependent solubility dissolves at pH values of more than 5.
|
Valid
Entry 115 |
19 |
The pharmaceutical formulation of claim 1, wherein the polymer having pH-dependent solubility dissolves at pH values of more than 6.
|
Valid
Entry 115 |
-
Infringement
Actavis Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
150 mg of oxcarbazepine300 mg of oxcarbazepine600 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,722,898 B2 |
1, 6, 7, 8, 11, 18, 19
|
Infringement
Entry 115Entry 418 |
150 mg of oxcarbazepine300 mg of oxcarbazepine600 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,910,131 B2 |
6, 7, 8, 11, 18, 19, 21
|
Infringement
Entry 115Entry 418 |
Actavis Laboratories FL Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,722,898 B2 |
1, 6, 7, 8, 11, 18, 19
|
Infringement
Entry 115
|
Generic oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,910,131 B2 |
6, 7, 8, 11, 18, 19, 21
|
Infringement
Entry 115
|
Actavis Pharma Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
150 mg of oxcarbazepine300 mg of oxcarbazepine600 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,722,898 B2 |
1, 6, 7, 8, 11, 18, 19
|
Infringement
Entry 115Entry 418 |
150 mg of oxcarbazepine300 mg of oxcarbazepine600 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,910,131 B2 |
6, 7, 8, 11, 18, 19, 21
|
Infringement
Entry 115Entry 418 |
Anda Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,722,898 B2 |
1, 6, 7, 8, 11, 18, 19
|
Infringement
Entry 115
|
Generic oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,910,131 B2 |
6, 7, 8, 11, 18, 19, 21
|
Infringement
Entry 115
|
Watson Laboratories, Inc. (Connecticut)
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
150 mg of oxcarbazepine300 mg of oxcarbazepine600 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,722,898 B2 |
1, 6, 7, 8, 11, 18, 19
|
Infringement
Entry 115Entry 418 |
150 mg of oxcarbazepine300 mg of oxcarbazepine600 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 150 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 300 mg of oxcarbazepineGeneric oxcarbazepine extended-release tablets, containing 600 mg of oxcarbazepine | US 7,910,131 B2 |
6, 7, 8, 11, 18, 19, 21
|
Infringement
Entry 115Entry 418 |